Takeda TAK-881 Wins Pivotal Phase 2/3 in PID

Company Takeda Pharmaceutical (Osaka / Cambridge, MA) Event Type Phase 2/3 pivotal trial topline results — primary endpoint met Modality Plasma-derived immunoglobulin SC with recombinant human hyaluronidase Target IgG replacement / immune reconstitution Indication Primary Immunodeficiency Disease (PID) — adults and pediatric patients aged 2…